Press Release IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer’s Trial Moves Within Six Randomizations of Enrollment Closure 15 hours ago
Press Release IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer’s Trial Approaches Enrollment Closure and Q4 Topline Readout Aug 11
Press Release IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign Jul 29